The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy

  1. Jimenez-Fonseca, P.
  2. Foy, V.
  3. Raby, S.
  4. Carmona-Bayonas, A.
  5. Macía-Rivas, L.
  6. Arrazubi, V.
  7. Cacho Lavin, D.
  8. Hernandez San Gil, R.
  9. Custodio, A.
  10. Cano, J.M.
  11. Fernández Montes, A.
  12. Mirallas, O.
  13. Macias Declara, I.
  14. Vidal Tocino, R.
  15. Visa, L.
  16. Limón, M.L.
  17. Pimentel, P.
  18. Martínez Lago, N.
  19. Sauri, T.
  20. Martín Richard, M.
  21. Mangas, M.
  22. Gil Raga, M.
  23. Calvo, A.
  24. Reguera, P.
  25. Granja, M.
  26. Martín Carnicero, A.
  27. Hernández Pérez, C.
  28. Cerdá, P.
  29. Gomez Gonzalez, L.
  30. Garcia Navalon, F.
  31. Pacheco Barcia, V.
  32. Gutierrez Abad, D.
  33. Ruiz Martín, M.
  34. Weaver, J.
  35. Mansoor, W.
  36. Gallego, J.
  37. Montrer des auteurs +
Revue:
Therapeutic Advances in Medical Oncology

ISSN: 1758-8359,  1758-8340

Année de publication: 2023

Volumen: 15

Type: Article

DOI: 10.1177/17588359231157641 GOOGLE SCHOLAR lock_openAccès ouvert editor

Objectifs de Développement Durable

La source de données: Scopus